Zurück zu den Rankings

The Clorox Company (CLX)

Unterbewertet
Consumer DefensiveHousehold & Personal ProductsUnited States

Fundamental

53

Kurs

$80.03

Marktkapitalisierung

$9.89B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Clorox makes household staples sold under well-known names: bleach and cleaning sprays under its own Clorox brand, trash bags under Glad, charcoal under Kingsford, and personal-care and health products including Burt's Bees. It manufactures most of what it sells, ships it to large retailers, and relies on repeat, habitual purchases rather than one-off sales — a household restocks bleach or trash bags on a predictable cycle regardless of the wider economy.

Wie das Geld verdient wird

Revenue comes from selling packaged goods to a concentrated set of large retailers, who then resell to shoppers. Margins depend on the cost of raw materials such as resin and chemicals, on manufacturing efficiency, and on holding shelf space and brand loyalty against cheaper private-label alternatives that retailers sell alongside Clorox's own products. The company reports results across four segments split by product category and by U.S. versus international markets.

Umsatz nach Segment

Health and Wellness38.1%

Cleaning and disinfecting products under Clorox, plus water filtration under Brita and vitamins under Natural Vitality.

Household28.3%

Trash bags under Glad, cat litter under Fresh Step and Scoop Away, and charcoal under Kingsford.

Lifestyle18.4%

Food products including Hidden Valley dressings, and personal care through Burt's Bees.

International15.1%

The same core product categories sold outside the United States, mainly in Latin America and Canada.

Wettbewerbsvorteil

Marke · Schmal

Names like Clorox, Glad and Kingsford have been the default choice on U.S. shelves for generations, which lets the company hold shelf space and charge more than an unbranded equivalent. The advantage is narrow: retailer store brands compete directly in nearly every category, and a large retailer with real pricing leverage can push back hard on Clorox's terms.

Was die Nachfrage antreibt

Defensiv

Cleaning products, trash bags and personal care items are routine, non-discretionary household purchases that people keep buying in a downturn, which makes volume relatively stable across the economic cycle. The bigger swings in results tend to come from input-cost inflation and from consumers trading down to private label when money is tight, not from skipping the purchase altogether.

Wichtigste Risiken

  • Retailer concentration — With Walmart alone worth nearly 27% of net sales, large retailers have the leverage to demand better pricing terms or to favour their own private-label products over Clorox's brands.
  • Input cost and supply chain disruption — Volatile commodity, packaging, labour, energy and logistics costs, along with the risk of supply disruption from conflicts such as those in Ukraine, the Middle East, or tensions between China and Taiwan, can raise costs faster than prices can be adjusted.
  • Cybersecurity — The company depends heavily on information technology systems and has already suffered a major cyberattack, in August 2023, that disrupted operations; a repeat incident could again halt production and shipments.
  • Private-label competition — Store-brand alternatives, often priced well below Clorox's products, compete in nearly every category the company sells in, forcing continued spending on marketing and innovation to defend market share.

Kundenkonzentration

Die größten Kunden machen 27 % des Umsatzes aus

Walmart and its affiliates accounted for nearly 27% of net sales in fiscal 2025, giving a single retailer significant leverage over shelf placement, promotional terms and pricing.

Die Argumente dafür

Buyers argue that Clorox's brands are habit-forming staples that hold shelf space no private label can fully dislodge, and that the company's cost-savings programme and full recovery from the 2023 cyberattack position it to grow margins even on roughly flat sales.

Die Argumente dagegen

Sellers worry that with Walmart alone worth over a quarter of sales, Clorox has limited room to push back on retailer demands, and that persistent private-label competition plus input-cost inflation could keep squeezing volumes and margins at the same time.

Written by the editors, published on 18. August 2026

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

P/E: 1127.5Score: 52Market cap: $3.12T

Reckitt's Lysol is the closest rival to Clorox's core disinfecting bleach, sprays and wipes, fighting for the same shelf space and the same household and professional cleaning budgets in North America.

P/E: 30.3Score: 69Market cap: $22.68B

Church & Dwight sells Arm & Hammer cleaning and laundry additives, cat litter and personal care to the same value-minded U.S. grocery and mass-market shopper Clorox depends on.

P/E: 21.9Score: 56Market cap: $346.41B

P&G's Mr. Clean, Swiffer, Dawn and Febreze compete directly with Clorox's home-cleaning lines for the same retail shelf and promotional slots, backed by far larger advertising and R&D budgets.

P/E: 33.7Score: 58Market cap: $68.97B

Colgate-Palmolive's home-care brands — Fabuloso, Ajax, Murphy Oil Soap — target the same surface-cleaning customer in the United States and in Clorox's Latin American markets.

S. C. Johnson & Son, Inc.Not tracked

This privately held U.S. group competes across several Clorox aisles at once: Windex and Scrubbing Bubbles against Clorox cleaners, Ziploc against Glad bags and wraps, Glade against home fragrance.

Unilever PLCNot tracked

Unilever competes with Clorox on two fronts: Domestos and Cif bleach and surface cleaners outside the U.S., and Dove, Vaseline and Simple against Burt's Bees in natural personal care.

Bilanz & Liquidität

Umsatz

$6.76B

Letzte 12 Monate (bis 31.3.2026)

Nettogewinn

$756M

Letzte 12 Monate (bis 31.3.2026)

Freier Cashflow

$761M

Gesamtes Eigenkapital

$321M

Gesamtverbindlichkeiten

$5.08B

Current Ratio

0.84

Zinsdeckungsgrad

-

Schulden/EBITDA

3.94

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallUnterbewertet

Innerer Wert

$108.06

Aktueller Kurs

$80.03

Sicherheitsmarge

+25.9%

Innerer-Wert-Spanne

$70.24 - $145.88

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$100.76
Diskontierter Cashflow (DCF):$193.39
Gewinnmultiplikator (P/E):$71.12
Graham-Wachstumsformel:$35.98
Ertragskraftwert (EPV):$64.12
Gerechtfertigtes P/B:$16.85
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:$136.15
Gewinn im Zyklusmittel:Nicht genügend Daten zur Berechnung
Umsatzmultiplikator:$65.36
Analystenkonsens:Halten (1B / 17H / 9S)
Letzte Gewinnüberraschung:-0.49%

Bewertungskennzahlen

P/E-Verhältnis

13.15

ROE

252.3%

P/B-Verhältnis

30.81

P/FCF

25.78

Bruttomarge

43.8%

ROIC

-

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

-

WACC

6.0%

ROIC − WACC

-

Fundamentalanalyse-Kriterien

Bestanden (12)

  • EPS shows upward trend
  • Gross Margin 43.8%
  • P/FCF 25.78
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 181.1%
  • Earnings Quality (OCF/NI) 0.76
  • Share Dilution -0.2%
  • Net Margin Trend 11.2% vs 9.9%
  • Piotroski F-Score 8/9

Nicht bestanden (11)

  • EPS CAGR 4.22%
  • Price CAGR -3.51%
  • P/B Ratio 30.81
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y -1.8%
  • Analyst Consensus 4% Buy
  • Earnings Surprise avg 1.8%

Nicht verfügbar (5)

  • ROIC NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

8/9

Starke finanzielle Gesundheit

score
criteria

Gewinnqualität

0.76

Mittel: Gewisse Differenz zwischen Gewinn und Cashflow

Aktienverwässerung

-0.2%

Aktienrückkäufe. Aktionärsfreundlich

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Ms. Linda J. RendleCEO & Chairman47
Mr. Luc BelletExecutive VP & CFO46
Mr. Chris T. HyderExecutive VP & COO50
Ms. Nina BartonExecutive VP and Chief Growth & Strategy Officer51
Ms. Laura E. PeckVP, Chief Accounting Officer & Corporate Controller48
Ms. Chau BanksSenior VP and Chief Information & Data Officer56
Ms. Kirsten M. MarrinerExecutive VP & Chief Administrative Officer52
Ms. Lisah BurhanVice President of Investor Relations-
Ms. Angela C. HiltExecutive VP, Chief Legal & External Affairs Officer and Corporate Secretary53
Mr. Eric Sean SchwartzSenior VP & Chief Marketing Officer53

Prüfungsrisiko

7

Vorstandsrisiko

3

Vergütungsrisiko

6

Aktionärsrechterisiko

8

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-08-07

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-04-30

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-08-03

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for CLX, sourced from Markets Gazette.

  • 8/3/2026POSITIVE
    Clorox Expects Full-Year Sales Boost From Purell Deal

    The Clorox Company announced fiscal fourth-quarter earnings that surpassed analyst forecasts, signaling resilience despite challenges. While sales volumes were down and the recent acquisition of GOJO Industries, the maker of Purell, incurred additional logistics costs, the overall financial performance indicates effective management. The company anticipates a full-year sales boost stemming from the Purell integration, suggesting a positive outlook for future revenue streams. Investors will be watching the successful integration of GOJO and its impact on Clorox's market position and profitability in the coming quarters.

via Markets Gazette